Controversy over Mild Stroke
Mild stroke patients are a special and controversial population. Mild stroke patients usually have a naturally good prognosis, and thrombolysis can alleviate the symptoms of mild stroke effectively, but thrombolysis increase the risk of bleeding. If all mild stroke patients are treated with thrombolytic therapy, these patients with good prognosis may bear additional thrombolytic costs and bleeding risk. In fact, 29% of patients did not receive thrombolytic therapy because of slight or rapid improvement of symptoms, resulting in a poor prognosis at 90 days. In the early stage of the disease, the potential severity of mild stroke may be underestimated due to mild symptoms, so as to miss the opportunity of thrombolysis and lead to poor prognosis.